A phase Ib/II study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL).

被引：0
|
作者：
Li, Jianyong
Zhou, Keshu
Nian, Weiqi
Cui, Guohui
Wang, Jishi
Zhang, Xiaoping
Cen, Hong
Li, Fei
Yi, Shuhua
Feng, Ru
Xu, Chongyuan
Qian, Wenbin
Liu, Lihong
Li, Caixia
Zhao, Xielan
Chen, Zi
Qiao, Junxiao
Zhang, Hongli
Ahmad, Mohammad
Zhai, Yifan
机构：
[1] Jiangsu Prov Hosp, Nanjing, Peoples R China
[2] Henan Canc Hosp, Zhengzhou, Peoples R China
[3] Chongqing Canc Hosp, Chongqing, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[5] Guizhou Med Univ, Affiliated Hosp, Guiyang, Peoples R China
[6] Southeast Univ, Zhongda Hosp, Nanjing, Peoples R China
[7] Guangxi Med Univ, Dept Med Oncol, Affiliated Canc Hosp, Nanning, Peoples R China
[8] Nanchang Univ, Affiliated Hosp 1, Nanchang, Peoples R China
[9] Chinese Acad Med Sci, Hematol Hosp, Beijing, Peoples R China
[10] Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China
[11] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Hangzhou, Peoples R China
[12] Hebei Med Univ, Tumor Hosp Hebei Prov, Hosp 4, Shijiazhuang, Peoples R China
[13] Suzhou First Peoples Hosp, Suzhou, Peoples R China
[14] Cent South Univ, Xiangya Hosp, Changsha, Peoples R China
[15] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China
[16] Ascentage Pharma Grp Inc, Rockville, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7543
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Wierda, William G.
    Dorritie, Kathleen A.
    Munoz, Javier
    Stephens, Deborah M.
    Solomon, Scott R.
    Gillenwater, Heidi H.
    Gong, Lucy
    Yang, Lin
    Ogasawara, Ken
    Thorpe, Jerill
    Siddiqi, Tanya
    BLOOD, 2020, 136
  • [32] A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL)
    Shouse, Geoffrey
    Chen, Lu
    Siddiqi, Tanya
    Muir, Alex
    Brown, Jennifer
    Spurgeon, Stephen
    Danilov, Alexey
    LEUKEMIA & LYMPHOMA, 2023, 64 : S105 - S106
  • [33] A Phase II Study of Intermittent Duvelisib Dosing in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Shouse, Geoffrey P.
    Chen, Lu
    Siddiqi, Tanya
    Muir, Alex
    Brown, Jennifer R.
    Spurgeon, Stephen E.
    Danilov, Alexey
    BLOOD, 2023, 142
  • [34] Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Rogers, Kerry A.
    Thompson, Philip A.
    Allan, John N.
    Coleman, Morton
    Sharman, Jeff P.
    Cheson, Bruce D.
    Izumi, Raquel
    Frigault, Melanie M.
    Quah, Cheng
    Raman, Rakesh K.
    Wang, Min Hui
    Kipps, Thomas J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S282 - S283
  • [35] Acquired Mutations in Patients (Pts) with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) That Progressed in the ALPINE Study
    Brown, Jennifer R.
    Li, Jessica
    Eichhorst, Barbara F.
    Lamanna, Nicole
    O'Brien, Susan M.
    Tam, Constantine S.
    Qiu, Luqui
    Ramakrishnan, Vanitha
    Huang, Ruiqi
    Shi, Yang
    Idoine, Adam
    Salmi, Tommi
    Cohen, Aileen Cleary
    Shadman, Mazyar
    BLOOD, 2023, 142
  • [36] BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
    Ozcan, Muhit
    Lavie, David
    Chaudhry, Arvind
    Zhou, Xuan
    Paydar, Ima
    Farooqui, Mohammed Z. H.
    Ghia, Paolo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
    Ailawadhi, Sikander
    Chen, Zi
    Huang, Bo
    Paulus, Aneel
    Collins, Mary C.
    Fu, Lei
    Li, Mingyu
    Ahmad, Mohammad
    Men, Lichuang
    Wang, Hengbang
    Davids, Matthew S.
    Liang, Eric
    Mekala, Divya J.
    He, Zhicong
    Lasica, Masa
    Yannakou, Costas K.
    Parrondo, Ricardo
    Glass, Laura
    Yang, Dajun
    Chanan-Khan, Asher
    Zhai, Yifan
    CLINICAL CANCER RESEARCH, 2023, 29 (13) : 2385 - 2393
  • [38] EXPOSURE RESPONSE (E-R) RELATIONSHIPS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
    Chen, Y.
    Balasubramanian, N.
    Cummings, J.
    Lin, H.
    Ou, S.
    Tuazon, S.
    Perna, S.
    Ogasawara, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S87 - S87
  • [39] A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
    Maddocks, Kami
    Hertlein, Erin K.
    Flynn, Joseph M.
    Andritsos, Leslie A.
    Wagner, Amy J.
    Chen, Timothy L.
    Phelps, Mitch A.
    Grever, Michael R.
    Johnson, Amy J.
    Byrd, John C.
    Jones, Jeffrey A.
    BLOOD, 2012, 120 (21)
  • [40] Zanubrutinib vs ibrutinib in relapsed/ refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
    Brown, Jennifer
    O'Brien, Susan M.
    Tam, Constantine S.
    Eichhorst, Barbara
    Qiu, Lugui
    Yang, Keri
    Wu, Ken
    Salmi, Tommi
    Barnes, Gisoo
    Lamanna, Nicole
    LEUKEMIA & LYMPHOMA, 2023, 64 : S79 - S80
12345